Re: Xu et al.: Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors (Ophthalmology. 2018;125:1279-1286)
Ophthalmology
.
2018 Nov;125(11):e80-e81.
doi: 10.1016/j.ophtha.2018.05.025.
Authors
Mohab Eldeeb
1
,
Omar Hegazy
2
,
Mohamed Ali Eldeeb
3
Affiliations
1
Department of Ophthalmology, St. Michael's Hospital, Toronto, Canada.
2
Department of Ophthalmology, Ain Shams University, Cairo, Egypt.
3
Department of Ophthalmology, Samaya Specialized Center, Abu Dhabi, United Arab Emirates. Electronic address: meldeeb@eim.ae.
PMID:
30318046
DOI:
10.1016/j.ophtha.2018.05.025
No abstract available
Publication types
Letter
Comment
MeSH terms
Endophthalmitis*
Humans
Intravitreal Injections
Ranibizumab
Vascular Endothelial Growth Factor A*
Substances
Vascular Endothelial Growth Factor A
Ranibizumab